



## Current Agreements

**Dealdoc**

### **Contract service agreement for Allomap testing**

Diaxonhit  
Hospital of University of Strasbourg

Jan 12 2015

## Contract service agreement for AlloMap testing

<b>Companies:</b>	<a href="#">Diaxonhit</a> <a href="#">Hospital of University of Strasbourg</a>
<b>Announcement date:</b>	Jan 12 2015
<b>Deal value, US\$m:</b>	n/d

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

### Details

<b>Announcement date:</b>	Jan 12 2015
<b>Industry sectors:</b>	Academic Diagnostic
<b>Asset type:</b>	Technology
<b>Therapy areas:</b>	Cardiovascular Hospital care » Rehabilitation medicine
<b>Technology types:</b>	Diagnostics » Molecular diagnostics
<b>Deal components:</b>	Contract service
<b>Geographic focus:</b>	Europe

### Financials

<b>Deal value, US\$m:</b>	n/d
---------------------------	-----

### Termsheet

Diaxonhit has entered into an agreement with the Strasbourg University Hospital (HUS) to be Diaxonhit's dedicated laboratory for AlloMap testing in Europe.

Under this agreement, all testing activities for Europe will be performed in the HUS Central Immunology Laboratory, under the authority and exclusive responsibility of HUS and its scientific director, Professor Seiamak Bahram.

A dedicated team of seasoned technical staff and biologists will perform AlloMap within a well-defined environment, using dedicated instruments that are currently being implemented.

Staff training will be initiated soon by Diaxonhit and CareDx in order for the laboratory to become operational during 2015.

### Press Release

CareDx Announces Its Commercial European Partner Diaxonhit Has Selected Strasbourg University Hospital To Perform AlloMap® Testing In Europe

BRISBANE, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that its exclusive commercial partner in Europe, Diaxonhit (Alternext: ALEHT, FR0004054427), a French leader in specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, has entered into an agreement with the Strasbourg University Hospital (HUS) to be Diaxonhit's dedicated laboratory for AlloMap testing in Europe. Under this agreement, all testing activities for Europe will be performed in the HUS Central Immunology Laboratory, under the authority and exclusive responsibility of HUS and its scientific director, Professor Seiamak Bahram. A dedicated team of seasoned technical staff and biologists will perform AlloMap within a well-defined environment, using dedicated

instruments that are currently being implemented. Staff training will be initiated soon by Diaxonhit and CareDx in order for the laboratory to become operational during 2015.

The agreement with HUS is a significant step towards providing European heart transplant recipients and their caregivers with AlloMap as part of their overall post-transplant surveillance and care. In parallel, Diaxonhit is working with individual European country health authorities to develop additional health economic data that may be required to obtain reimbursement coverage for AlloMap.

"With the selection of the Strasbourg University Hospitals, a prestigious institution, we have achieved another key milestone for Diaxonhit, as it will facilitate AlloMap's implementation in Europe. We were impressed by the enthusiasm and dedication of the HUS staff, and feel that AlloMap testing will be performed by the best possible team," stated Dr. Loïc Maurel, President of the Management Board of Diaxonhit.

According to Peter Maag, President and CEO of CareDx, "We are pleased and excited to have HUS as the European laboratory partner to perform AlloMap testing. Their world-class experience and expertise with molecular diagnostics and transplant care make them well-suited to perform this non-invasive test that will positively impact care among European heart transplant recipients."

#### About AlloMap®

AlloMap Molecular Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. AlloMap is performed in the CLIA-certified and CAP-accredited clinical laboratory at CareDx and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Recommended use of AlloMap for heart transplant rejection surveillance is included in the International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the care of heart transplant recipients, published in August, 2010. These guidelines represent the worldwide standard for the care of heart transplant patients.

#### About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. For more information, please visit: [www.CareDxInc.com](http://www.CareDxInc.com).

#### About Diaxonhit

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in in vitro diagnostics, involved from research to commercialization of specialty diagnostic products in the fields of transplantation, infectious diseases and cancer. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment, quality control products and rapid tests, including Tetanus Quick Stick®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest commercial partner worldwide. The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering its three main specialty areas: transplantation, immuno-infection and cancer. Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of both the NYSE Alternext OSEO Innovation and the Next Biotech indices. For more information, please visit: <http://www.diaxonhit.com>.

#### Filing Data

*Not available.*

#### Contract

*Not available.*